Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

July 20, 2021 Auto Bot Biosimilars, Clinical Trial, P-III, Proposed Biosimilar, Samsung Bioepis, Stelara, ustekinumab 0

Shots:

  • The company initiates P-III clinical trial to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 vs Stelara in a ratio (1:1) in patients with moderate to severe plaque psoriasis
  • Additionally, patients either continue on Stelara or transition to SB17 @28wks. The IPs (SB17 or Stelara, q12w) will be administered @0, 4 and for up to 40wks. and the last assessment will be performed @52wks.
  • The company continues to advance a broad pipeline of biosimilar candidates covering therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology, and gastroenterology

Click here to read full press release/ article | Ref:  Samsung Bioepis | Image: PR Newswire

The post Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab) first appeared on PharmaShots.